Anti-phospho-tau antibodies to GSK3 sites on tau are once applied to immunotherapy for AD, such as PHF-1 antibody (Boutajangout et al., 2011; Liu et al., 2016), targeting epitope pSer396/pSer404 of tau (Boutajangout et al., 2011; Liu et al., 2016), antibodies JNJ-63733657, PT3 (Chai et al., 2011; d'Abramo et al., 2013) and its humanized version, hTP3 (Van Kolen et al., 2020), targeting epitope pThr212/pThr217, and antibody PHF-13 (Sankaranarayanan et al., 2015) targeting epitope pThr231 and pSer396. This evidence concerns the gene MAPT and Alzheimer disease.